{"ticker": {"uuid": "e6dc4a71-29e3-43c6-8ed2-e55db4dcc6b9", "symbol": "TLSI", "name": "TriSalus Life Sciences Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of TriSalus Life Sciences, Inc. \u2013 NASDAQ:TLSI", "summary": "This article provides financial information for TriSalus Life Sciences, Inc. (NASDAQ: TLSI) on TradingView. It specifically highlights the company's \"Price to sales forward\" metric, displayed within the financials section of its profile. The content indicates market data and refe", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T19:40:15", "published_display": "12 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSIW SEC Filings - TriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page on StockTitan provides access to TriSalus Life Sciences Inc. (TLSIW) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. Each filing is accompanied by an AI-generated summary, sentiment analysis, impact scores, and end-of-day st", "url": "https://www.stocktitan.net/sec-filings/TLSIW/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:40:15", "published_display": "10 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Light Asset Management, Mathew Arens report 10.74% stake in TriSalus (TLSI)", "summary": "First Light Asset Management, LLC and Mathew P. Arens have jointly reported a beneficial ownership of 6,596,242 shares of TriSalus Life Sciences, Inc. (TLSI), representing a 10.74% stake. This disclosure, an amendment to a prior Schedule 13G filing, indicates shared voting and di", "url": "https://www.stocktitan.net/sec-filings/TLSI/schedule-13g-a-tri-salus-life-sciences-inc-amended-passive-investment-107a0cc57f72.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:42:31", "published_display": "07 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus (TLSI) CFO has shares withheld to cover RSU tax obligations", "summary": "TriSalus Life Sciences, Inc. (TLSI) Chief Financial Officer David Patience had 14,650 shares of common stock withheld at $4.46 per share to cover tax obligations from the vesting of restricted stock units. This was a routine tax-related share withholding, not an open-market sale.", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-4-tri-salus-life-sciences-inc-insider-trading-activity-bde8b19347ab.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:09:53", "published_display": "06 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSI - TriSalus Life Sciences Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of TriSalus Life Sciences Inc (TLSI), including its current stock price, market capitalization, income, sales, and various financial ratios. It also presents volatility metrics, insider and institutional ownership, and performan", "url": "https://finviz.com/stock?t=TLSI&p=d&ty=ocv&b=2&r=m1&e=2026-04-25", "source_name": "Finviz", "published_at": "2026-07-02T13:11:18", "published_display": "02 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell 3000E Value Benchmark", "summary": "TriSalus Life Sciences, Inc. (NasdaqGM:TLSI) has been removed from the Russell 3000E Value Benchmark, alongside other Russell indices such as the Russell Small Cap Comp Value, Russell 3000 Value, Russell 2500 Value, Russell Microcap Value, and Russell 2000 Value Benchmark. This o", "url": "https://www.marketscreener.com/news/trisalus-life-sciences-inc-nasdaqgm-tlsi-dropped-from-russell-3000e-value-benchmark-ce7f5fddd888f027", "source_name": "www.marketscreener.com", "published_at": "2026-07-01T23:44:42", "published_display": "01 Jul 2026 23:44", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus (TLSI) CEO Mary Szela acquires 3,990 ESPP shares, now holds 1.08M", "summary": "TriSalus Life Sciences CEO Mary T. Szela acquired 3,990 shares of common stock at $3.87 per share through the company's Employee Stock Purchase Plan (ESPP). This transaction, exempt under Rule 16b-3, increases her direct holdings to 1,077,683 TriSalus shares. The acquisition high", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-4-tri-salus-life-sciences-inc-insider-trading-activity-1f55922f8ce8.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:48", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences (TLSI) CCO acquires 561 ESPP shares", "summary": "TriSalus Life Sciences (TLSI) Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.87 per share through the company\u2019s Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increases his direct holdings to 128,319 shares. The filing", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-4-tri-salus-life-sciences-inc-insider-trading-activity-0a5e9756abcc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:48", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of TriSalus Life Sciences, Inc. \u2013 NASDAQ:TLSI", "summary": "This article provides the \"Price to earnings forward\" value for TriSalus Life Sciences, Inc. (NASDAQ: TLSI). The specific value for this financial metric is not disclosed in the provided content, but the article indicates it is a historical value without current trading data. It ", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T05:41:04", "published_display": "01 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences (TLSI) CMO awarded RSUs and 120,000-share option grant", "summary": "TriSalus Life Sciences' Chief Medical Officer, Richard Henry, has been awarded new equity compensation including 60,000 restricted stock units and an option grant for 120,000 shares of common stock at an exercise price of $4.74 per share. These awards are subject to vesting sched", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-4-tri-salus-life-sciences-inc-insider-trading-activity-8da0ef34f006.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:40:07", "published_display": "30 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus (TLSI) CMO discloses common stock and option holdings in Form 3", "summary": "TriSalus Life Sciences, Inc.'s new Chief Medical Officer, Marshall Richard Henry, has disclosed his initial equity holdings via a Form 3 filing, effective June 29, 2026. The filing reveals he holds 30,000 shares of common stock acquired before his appointment, along with employee", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-3-tri-salus-life-sciences-inc-initial-statement-of-beneficial-ow-310d4d32b1dc.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:40:07", "published_display": "29 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 TriSalus Life Sciences Inc For: 29 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for TriSalus Life Sciences Inc. on June 29, 2026. The brief piece includes the stock ticker TLSI and its price performance, but provides no further details about the content of the Form 4 filing.", "url": "https://ca.investing.com/news/stock-market-news/form-4-trisalus-life-sciences-inc-for-29-june-93CH-4712527", "source_name": "Investing.com Canada", "published_at": "2026-06-29T18:40:07", "published_display": "29 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell Small Cap Comp Value Benchmark", "summary": "TriSalus Life Sciences, Inc. (NasdaqGM:TLSI) has been removed from the Russell Small Cap Comp Value Benchmark. The company's stock experienced a 9.61% increase despite this news. This development follows recent announcements of the company being dropped from other Russell benchma", "url": "https://www.marketscreener.com/news/trisalus-life-sciences-inc-nasdaqgm-tlsi-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8df625", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:11:30", "published_display": "29 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc.(NasdaqGM: TLSI) dropped from Russell 2500 Value Benchmark", "summary": "TriSalus Life Sciences, Inc. (NasdaqGM: TLSI) has been removed from the Russell 2500 Value Benchmark index. This news, published on June 28, 2026, also noted related updates, including the company's prior removal from the Russell 3000 Value Benchmark. TriSalus Life Sciences is an", "url": "https://www.marketscreener.com/news/trisalus-life-sciences-inc-nasdaqgm-tlsi-dropped-from-russell-2500-value-benchmark-ce7f5fded880f025", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T21:12:00", "published_display": "28 Jun 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc. Actuals & Estimates (NASDAQ:TLSI)", "summary": "This article provides an overview of TriSalus Life Sciences, Inc. (TLSI) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report dates. The article als", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:10", "published_display": "26 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7", "summary": "CCORF has reiterated its Buy rating for TriSalus Life Sciences (TLSI.US) and maintained its price target at $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72034350/ccorf-maintains-trisalus-life-sciences-tlsius-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-26T05:39:31", "published_display": "26 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for TriSalus Life Sciences, Inc. (TLSI) stock, including analyst ratings, historical price performance, and financial data. It indicates that 5 analysts offer a price target with a max estimate of $11.00 and a min estimate of $7.00", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T04:40:10", "published_display": "26 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI", "summary": "Pomerantz LLP is investigating TriSalus Life Sciences Inc. (NASDAQ: TLSI) on behalf of investors for potential securities fraud. This investigation follows TriSalus's announcement of lower-than-expected Q1 2026 revenue and a reduced full-year revenue guidance, primarily due to co", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-trisalus-life-sciences-inc---tlsi-302808830.html", "source_name": "PR Newswire", "published_at": "2026-06-25T10:00:00", "published_display": "25 Jun 2026 10:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences (TLSI) Gains 3.23% as Shares Test Resistance at $4.37 - Ichimoku Kumo Twist", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNQUpqV0htTVBEeG56T0VrX29EeURzclFxLUgzNHc5VFVFSVdyZXdWM3QxVVIzSU9HeHZXWU5UWlRRNS1qV0pLcEV6NEIwZmtfM1VGeVphOUZGbGg2andOdlByTUQ0RzUwclJYQ2hnV2JzWXpSd3pKNk1ZRnVRTm8xeU1JNXlkSE9oTElVTTBxRUxzNUluTTJEOHBaZzVsZXl5bE40TVQxQlBlNWVrenlz?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T00:36:20+00:00", "published_display": "25 Jun 2026 00:36", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSIW) Institutional Confidence", "summary": "This article provides details on the institutional confidence in TriSalus Life Sciences Inc. (TLSIW), listing institutional holdings and changes in share percentages. Several large institutions have significantly reduced their stakes, while others like Fort Baker Capital Manageme", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsiw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T12:10:16", "published_display": "18 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of TriSalus Life Sciences Inc (TLSI), noting its current price momentum score of 7.30 and its trading range between a resistance level of $4.56 and a support level of $3.12. It details various technical indicators and moving averages, wh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsi/technical", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:29", "published_display": "18 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "TriSalus Life Sciences Inc (TLSI) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have a consensus price target of $11.00 for TLSI, with most recommending a \"Buy\" rating. The company's expected revenue for the ne", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsi/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:29", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSIW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a brief overview of TriSalus Life Sciences Inc. (TLSIW) focusing on its dividend and stock split history. It states that no dividend payments or stock splits have been recorded for the company. The page also displays current stock price information and links", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsiw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T16:40:24", "published_display": "17 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm", "summary": "The Schall Law Firm has announced an investigation into TriSalus Life Sciences, Inc. (NASDAQ: TLSI) for potential securities law violations. This follows TriSalus's Q1 2026 financial results, which showed a year-over-year revenue decline and a cut in full-year guidance, attribute", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313563/0/en/tlsi-investors-have-opportunity-to-join-trisalus-life-sciences-inc-fraud-investigation-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T13:40:24", "published_display": "17 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Richard Marshall Accepts New Role at TriSalus Life Sciences", "summary": "Richard Marshall, M.D., has been appointed Chief Medical Officer at TriSalus Life Sciences, effective June 29, 2026. Dr. Marshall, previously the company's medical director since January 2025, will now lead the medical strategy and clinical leadership for TriSalus, focusing on ad", "url": "https://www.mpo-mag.com/breaking-news/richard-marshall-accepts-new-role-at-trisalus-life-sciences/", "source_name": "Medical Product Outsourcing", "published_at": "2026-06-16T14:38:55", "published_display": "16 Jun 2026 14:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery\u2122 in Liver Cancer", "summary": "TriSalus Life Sciences announced a virtual KOL event on June 24, 2026, to discuss new real-world evidence for its Pressure-Enabled Drug Delivery (PEDD) technology in liver cancer. The study shows a 48% improvement in drug delivery to target tumors and reduced complications, with ", "url": "https://www.stocktitan.net/news/TLSI/tri-salus-life-sciences-to-host-virtual-kol-event-on-june-24-bs38zwbz7j56.html", "source_name": "Stock Titan", "published_at": "2026-06-10T12:08:58", "published_display": "10 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSI INVESTOR ALERT: Holzer & Holzer, LLC Investigation of TriSalus Life Sciences, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNek5HVWI3Nl9hMjdmS0ZuaDZrT2N5NDFwOHkyaGNwS3Bld01wWHhSZHZtVTBZRkkwcERIdGYzWTZlcmxfOXZPLTJyaDJfZkRRX3U2eE1oekg4Rmp0MnRWSlFwZVFkTThSekszalF1TkVNczdqZDFuek1jM0VTWWl0VGQza1dNUDZ2SjVMQWlGSVdkMHZKd1dreDlHMXRoV0Z2QWdiaXRaQS1mYTVONHpkOXpVeXVDaXhYRGhUOHdUMmxtdmUtZjc1ZUkwXzR2QzFxUkQ1dHcyTEo5NnVlS1d4SGRiTXpLelJt?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TriSalus Life Sciences (TLSI) Turns Q1 2026 Profit Challenging Persistent Loss Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc. Stock 12\u2011Month Price Target Cut to $8.8, Implies 93% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOdVdfNXU1eHBCOENSVnZvNE5zUTlWd3VSTlNpRnpaOWtvYTVUSHhLSFI2WDdabkRtSUx6Y0FmSXVzeFhXVGNodkltcy00QUdKWk9iWEdoSndvOTdYX2VZWnNaOS1SX0VXTUItVHNjVTUxRWZaV2prVHVzbjNhLTVoWGVGYWp2VzJSZEhPUV9LVEZfVFdqNnRjNUw2bFNRYmpQbzlEbXBQbUdDMkVUaTdjSEhZUlN2OXVTREoyZUxpMDhicDQySm9uWHZ4a016Yk1QS05kTlVoWWlpYV9neEE?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...", "summary": "", "url": "https://finance.yahoo.com/news/trisalus-life-sciences-inc-tlsi-050126283.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:01:26+00:00", "published_display": "13 May 2026 05:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/c4e42cf1-cd14-3d4c-953c-8a5c394688b8/trisalus-life-sciences-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-13T02:06:19+00:00", "published_display": "13 May 2026 02:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/96ac63de-91a2-3449-81df-794f75693150/trisalus-life-sciences%2C-inc..html", "source_name": "Moby", "published_at": "2026-05-13T00:47:35+00:00", "published_display": "13 May 2026 00:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Swings to Q1 Earnings, Revenue Declines", "summary": "", "url": "https://finance.yahoo.com/news/trisalus-life-sciences-swings-q1-204849720.html", "source_name": "MT Newswires", "published_at": "2026-05-12T20:48:49+00:00", "published_display": "12 May 2026 20:48", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRISALUS LIFE SCIENCES ($TLSI) Releases Q1 2026 Earnings | TLSI Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQUWg0c2pyRjVFTFlTd1Zlc3J4OVZ1eWxHeWpreTJsNmJ3bDZMcDRseXFQSV9aelFSZGdfd3RtZWdydkxPaG5XMDI2di0zSEVyWnRpcUFtMGlSNHoxY282MUVzLVJhMWgtalp6VTRNQ016N3ZhejBvVU02MUpJNlR5RGYwOVo4TGpPdUVqcFpvWXV4TVdxT1N0MFFaSQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc. (TLSI) Releases Q1 2026 Earnings: Revenue Miss but EPS Beats", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQWXQtWHZINFhvdFZ0eW5EQ05ZZFlvM2hpaXZnWGhqaUhrVGhMMVdHWllzVDBtMFZuUHRIY1RpNTAzYkNPTEFQWUkyR1FTZmlVOFcxcUo2SzZrTGpya1F4NWFCVlllNVlHNG9PeUU1aTJpOGF6cXV3VEZLeEJhT28zRVE0Mlg4QXZ1VkFZYy1OUzZlNXJmbWNsYThhS1hmdGtJZzI0bDZTRmdUWEpZcXR6enBPWTZjWlBmbFUzM0tFRVYxYl9rUlE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOckh5VFYzeGJPX3hxZHZNT0xQRXRfRUpKNTZCU2xodDJxUUVNYWxxVEhDVlZGRG81WVdWMWliMU5iWjllbW5RYkdxYS0wUFJ3d2JBQ2FGSEZza3U2SXk4RERFMWpvVEN5bVdoWmZQaml0V1RvVzhNb1lBejBJcy1QZzYxQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Reports Q1 2026 Result", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/earnings-watch-trisalus-life-sciences-132126206.html", "source_name": "GuruFocus.com", "published_at": "2026-05-11T13:21:26+00:00", "published_display": "11 May 2026 13:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/trisalus-tlsi-initiates-patient-enrollment-040117814.html", "source_name": "Insider Monkey", "published_at": "2026-05-10T04:01:17+00:00", "published_display": "10 May 2026 04:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Price to sales forward of TriSalus Life Sciences, Inc. \u2013 NASDAQ:TLSI", "summary": "This article provides financial information for TriSalus Life Sciences, Inc. (NASDAQ: TLSI) on TradingView. It specifically highlights the company's \"Price to sales forward\" metric, displayed within the financials section of its profile. The content indicates market data and refe", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T19:40:15", "published_display": "12 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSIW SEC Filings - TriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page on StockTitan provides access to TriSalus Life Sciences Inc. (TLSIW) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. Each filing is accompanied by an AI-generated summary, sentiment analysis, impact scores, and end-of-day st", "url": "https://www.stocktitan.net/sec-filings/TLSIW/page-5.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:40:15", "published_display": "10 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Light Asset Management, Mathew Arens report 10.74% stake in TriSalus (TLSI)", "summary": "First Light Asset Management, LLC and Mathew P. Arens have jointly reported a beneficial ownership of 6,596,242 shares of TriSalus Life Sciences, Inc. (TLSI), representing a 10.74% stake. This disclosure, an amendment to a prior Schedule 13G filing, indicates shared voting and di", "url": "https://www.stocktitan.net/sec-filings/TLSI/schedule-13g-a-tri-salus-life-sciences-inc-amended-passive-investment-107a0cc57f72.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:42:31", "published_display": "07 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus (TLSI) CFO has shares withheld to cover RSU tax obligations", "summary": "TriSalus Life Sciences, Inc. (TLSI) Chief Financial Officer David Patience had 14,650 shares of common stock withheld at $4.46 per share to cover tax obligations from the vesting of restricted stock units. This was a routine tax-related share withholding, not an open-market sale.", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-4-tri-salus-life-sciences-inc-insider-trading-activity-bde8b19347ab.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:09:53", "published_display": "06 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSI - TriSalus Life Sciences Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of TriSalus Life Sciences Inc (TLSI), including its current stock price, market capitalization, income, sales, and various financial ratios. It also presents volatility metrics, insider and institutional ownership, and performan", "url": "https://finviz.com/stock?t=TLSI&p=d&ty=ocv&b=2&r=m1&e=2026-04-25", "source_name": "Finviz", "published_at": "2026-07-02T13:11:18", "published_display": "02 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell 3000E Value Benchmark", "summary": "TriSalus Life Sciences, Inc. (NasdaqGM:TLSI) has been removed from the Russell 3000E Value Benchmark, alongside other Russell indices such as the Russell Small Cap Comp Value, Russell 3000 Value, Russell 2500 Value, Russell Microcap Value, and Russell 2000 Value Benchmark. This o", "url": "https://www.marketscreener.com/news/trisalus-life-sciences-inc-nasdaqgm-tlsi-dropped-from-russell-3000e-value-benchmark-ce7f5fddd888f027", "source_name": "www.marketscreener.com", "published_at": "2026-07-01T23:44:42", "published_display": "01 Jul 2026 23:44", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus (TLSI) CEO Mary Szela acquires 3,990 ESPP shares, now holds 1.08M", "summary": "TriSalus Life Sciences CEO Mary T. Szela acquired 3,990 shares of common stock at $3.87 per share through the company's Employee Stock Purchase Plan (ESPP). This transaction, exempt under Rule 16b-3, increases her direct holdings to 1,077,683 TriSalus shares. The acquisition high", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-4-tri-salus-life-sciences-inc-insider-trading-activity-1f55922f8ce8.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:48", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences (TLSI) CCO acquires 561 ESPP shares", "summary": "TriSalus Life Sciences (TLSI) Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.87 per share through the company\u2019s Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increases his direct holdings to 128,319 shares. The filing", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-4-tri-salus-life-sciences-inc-insider-trading-activity-0a5e9756abcc.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:09:48", "published_display": "01 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of TriSalus Life Sciences, Inc. \u2013 NASDAQ:TLSI", "summary": "This article provides the \"Price to earnings forward\" value for TriSalus Life Sciences, Inc. (NASDAQ: TLSI). The specific value for this financial metric is not disclosed in the provided content, but the article indicates it is a historical value without current trading data. It ", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T05:41:04", "published_display": "01 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences (TLSI) CMO awarded RSUs and 120,000-share option grant", "summary": "TriSalus Life Sciences' Chief Medical Officer, Richard Henry, has been awarded new equity compensation including 60,000 restricted stock units and an option grant for 120,000 shares of common stock at an exercise price of $4.74 per share. These awards are subject to vesting sched", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-4-tri-salus-life-sciences-inc-insider-trading-activity-8da0ef34f006.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:40:07", "published_display": "30 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus (TLSI) CMO discloses common stock and option holdings in Form 3", "summary": "TriSalus Life Sciences, Inc.'s new Chief Medical Officer, Marshall Richard Henry, has disclosed his initial equity holdings via a Form 3 filing, effective June 29, 2026. The filing reveals he holds 30,000 shares of common stock acquired before his appointment, along with employee", "url": "https://www.stocktitan.net/sec-filings/TLSI/form-3-tri-salus-life-sciences-inc-initial-statement-of-beneficial-ow-310d4d32b1dc.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:40:07", "published_display": "29 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 TriSalus Life Sciences Inc For: 29 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for TriSalus Life Sciences Inc. on June 29, 2026. The brief piece includes the stock ticker TLSI and its price performance, but provides no further details about the content of the Form 4 filing.", "url": "https://ca.investing.com/news/stock-market-news/form-4-trisalus-life-sciences-inc-for-29-june-93CH-4712527", "source_name": "Investing.com Canada", "published_at": "2026-06-29T18:40:07", "published_display": "29 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell Small Cap Comp Value Benchmark", "summary": "TriSalus Life Sciences, Inc. (NasdaqGM:TLSI) has been removed from the Russell Small Cap Comp Value Benchmark. The company's stock experienced a 9.61% increase despite this news. This development follows recent announcements of the company being dropped from other Russell benchma", "url": "https://www.marketscreener.com/news/trisalus-life-sciences-inc-nasdaqgm-tlsi-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8df625", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:11:30", "published_display": "29 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc.(NasdaqGM: TLSI) dropped from Russell 2500 Value Benchmark", "summary": "TriSalus Life Sciences, Inc. (NasdaqGM: TLSI) has been removed from the Russell 2500 Value Benchmark index. This news, published on June 28, 2026, also noted related updates, including the company's prior removal from the Russell 3000 Value Benchmark. TriSalus Life Sciences is an", "url": "https://www.marketscreener.com/news/trisalus-life-sciences-inc-nasdaqgm-tlsi-dropped-from-russell-2500-value-benchmark-ce7f5fded880f025", "source_name": "www.marketscreener.com", "published_at": "2026-06-28T21:12:00", "published_display": "28 Jun 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc. Actuals & Estimates (NASDAQ:TLSI)", "summary": "This article provides an overview of TriSalus Life Sciences, Inc. (TLSI) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report dates. The article als", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:10", "published_display": "26 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7", "summary": "CCORF has reiterated its Buy rating for TriSalus Life Sciences (TLSI.US) and maintained its price target at $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72034350/ccorf-maintains-trisalus-life-sciences-tlsius-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-26T05:39:31", "published_display": "26 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for TriSalus Life Sciences, Inc. (TLSI) stock, including analyst ratings, historical price performance, and financial data. It indicates that 5 analysts offer a price target with a max estimate of $11.00 and a min estimate of $7.00", "url": "https://www.tradingview.com/symbols/NASDAQ-TLSI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T04:40:10", "published_display": "26 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI", "summary": "Pomerantz LLP is investigating TriSalus Life Sciences Inc. (NASDAQ: TLSI) on behalf of investors for potential securities fraud. This investigation follows TriSalus's announcement of lower-than-expected Q1 2026 revenue and a reduced full-year revenue guidance, primarily due to co", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-trisalus-life-sciences-inc---tlsi-302808830.html", "source_name": "PR Newswire", "published_at": "2026-06-25T10:00:00", "published_display": "25 Jun 2026 10:00", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences (TLSI) Gains 3.23% as Shares Test Resistance at $4.37 - Ichimoku Kumo Twist", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNQUpqV0htTVBEeG56T0VrX29EeURzclFxLUgzNHc5VFVFSVdyZXdWM3QxVVIzSU9HeHZXWU5UWlRRNS1qV0pLcEV6NEIwZmtfM1VGeVphOUZGbGg2andOdlByTUQ0RzUwclJYQ2hnV2JzWXpSd3pKNk1ZRnVRTm8xeU1JNXlkSE9oTElVTTBxRUxzNUluTTJEOHBaZzVsZXl5bE40TVQxQlBlNWVrenlz?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T00:36:20+00:00", "published_display": "25 Jun 2026 00:36", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSIW) Institutional Confidence", "summary": "This article provides details on the institutional confidence in TriSalus Life Sciences Inc. (TLSIW), listing institutional holdings and changes in share percentages. Several large institutions have significantly reduced their stakes, while others like Fort Baker Capital Manageme", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsiw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T12:10:16", "published_display": "18 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of TriSalus Life Sciences Inc (TLSI), noting its current price momentum score of 7.30 and its trading range between a resistance level of $4.56 and a support level of $3.12. It details various technical indicators and moving averages, wh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsi/technical", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:29", "published_display": "18 Jun 2026 06:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "TriSalus Life Sciences Inc (TLSI) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have a consensus price target of $11.00 for TLSI, with most recommending a \"Buy\" rating. The company's expected revenue for the ne", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsi/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:29", "published_display": "18 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSIW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a brief overview of TriSalus Life Sciences Inc. (TLSIW) focusing on its dividend and stock split history. It states that no dividend payments or stock splits have been recorded for the company. The page also displays current stock price information and links", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tlsiw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T16:40:24", "published_display": "17 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm", "summary": "The Schall Law Firm has announced an investigation into TriSalus Life Sciences, Inc. (NASDAQ: TLSI) for potential securities law violations. This follows TriSalus's Q1 2026 financial results, which showed a year-over-year revenue decline and a cut in full-year guidance, attribute", "url": "https://www.globenewswire.com/news-release/2026/06/17/3313563/0/en/tlsi-investors-have-opportunity-to-join-trisalus-life-sciences-inc-fraud-investigation-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T13:40:24", "published_display": "17 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Richard Marshall Accepts New Role at TriSalus Life Sciences", "summary": "Richard Marshall, M.D., has been appointed Chief Medical Officer at TriSalus Life Sciences, effective June 29, 2026. Dr. Marshall, previously the company's medical director since January 2025, will now lead the medical strategy and clinical leadership for TriSalus, focusing on ad", "url": "https://www.mpo-mag.com/breaking-news/richard-marshall-accepts-new-role-at-trisalus-life-sciences/", "source_name": "Medical Product Outsourcing", "published_at": "2026-06-16T14:38:55", "published_display": "16 Jun 2026 14:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery\u2122 in Liver Cancer", "summary": "TriSalus Life Sciences announced a virtual KOL event on June 24, 2026, to discuss new real-world evidence for its Pressure-Enabled Drug Delivery (PEDD) technology in liver cancer. The study shows a 48% improvement in drug delivery to target tumors and reduced complications, with ", "url": "https://www.stocktitan.net/news/TLSI/tri-salus-life-sciences-to-host-virtual-kol-event-on-june-24-bs38zwbz7j56.html", "source_name": "Stock Titan", "published_at": "2026-06-10T12:08:58", "published_display": "10 Jun 2026 12:08", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TLSI INVESTOR ALERT: Holzer & Holzer, LLC Investigation of TriSalus Life Sciences, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNek5HVWI3Nl9hMjdmS0ZuaDZrT2N5NDFwOHkyaGNwS3Bld01wWHhSZHZtVTBZRkkwcERIdGYzWTZlcmxfOXZPLTJyaDJfZkRRX3U2eE1oekg4Rmp0MnRWSlFwZVFkTThSekszalF1TkVNczdqZDFuek1jM0VTWWl0VGQza1dNUDZ2SjVMQWlGSVdkMHZKd1dreDlHMXRoV0Z2QWdiaXRaQS1mYTVONHpkOXpVeXVDaXhYRGhUOHdUMmxtdmUtZjc1ZUkwXzR2QzFxUkQ1dHcyTEo5NnVlS1d4SGRiTXpLelJt?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences (TLSI) Turns Q1 2026 Profit Challenging Persistent Loss Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc. Stock 12\u2011Month Price Target Cut to $8.8, Implies 93% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOdVdfNXU1eHBCOENSVnZvNE5zUTlWd3VSTlNpRnpaOWtvYTVUSHhLSFI2WDdabkRtSUx6Y0FmSXVzeFhXVGNodkltcy00QUdKWk9iWEdoSndvOTdYX2VZWnNaOS1SX0VXTUItVHNjVTUxRWZaV2prVHVzbjNhLTVoWGVGYWp2VzJSZEhPUV9LVEZfVFdqNnRjNUw2bFNRYmpQbzlEbXBQbUdDMkVUaTdjSEhZUlN2OXVTREoyZUxpMDhicDQySm9uWHZ4a016Yk1QS05kTlVoWWlpYV9neEE?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...", "summary": "", "url": "https://finance.yahoo.com/news/trisalus-life-sciences-inc-tlsi-050126283.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T05:01:26+00:00", "published_display": "13 May 2026 05:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/c4e42cf1-cd14-3d4c-953c-8a5c394688b8/trisalus-life-sciences-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-13T02:06:19+00:00", "published_display": "13 May 2026 02:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/96ac63de-91a2-3449-81df-794f75693150/trisalus-life-sciences%2C-inc..html", "source_name": "Moby", "published_at": "2026-05-13T00:47:35+00:00", "published_display": "13 May 2026 00:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Swings to Q1 Earnings, Revenue Declines", "summary": "", "url": "https://finance.yahoo.com/news/trisalus-life-sciences-swings-q1-204849720.html", "source_name": "MT Newswires", "published_at": "2026-05-12T20:48:49+00:00", "published_display": "12 May 2026 20:48", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRISALUS LIFE SCIENCES ($TLSI) Releases Q1 2026 Earnings | TLSI Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQUWg0c2pyRjVFTFlTd1Zlc3J4OVZ1eWxHeWpreTJsNmJ3bDZMcDRseXFQSV9aelFSZGdfd3RtZWdydkxPaG5XMDI2di0zSEVyWnRpcUFtMGlSNHoxY282MUVzLVJhMWgtalp6VTRNQ016N3ZhejBvVU02MUpJNlR5RGYwOVo4TGpPdUVqcFpvWXV4TVdxT1N0MFFaSQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences Inc. (TLSI) Releases Q1 2026 Earnings: Revenue Miss but EPS Beats", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQWXQtWHZINFhvdFZ0eW5EQ05ZZFlvM2hpaXZnWGhqaUhrVGhMMVdHWllzVDBtMFZuUHRIY1RpNTAzYkNPTEFQWUkyR1FTZmlVOFcxcUo2SzZrTGpya1F4NWFCVlllNVlHNG9PeUU1aTJpOGF6cXV3VEZLeEJhT28zRVE0Mlg4QXZ1VkFZYy1OUzZlNXJmbWNsYThhS1hmdGtJZzI0bDZTRmdUWEpZcXR6enBPWTZjWlBmbFUzM0tFRVYxYl9rUlE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOckh5VFYzeGJPX3hxZHZNT0xQRXRfRUpKNTZCU2xodDJxUUVNYWxxVEhDVlZGRG81WVdWMWliMU5iWjllbW5RYkdxYS0wUFJ3d2JBQ2FGSEZza3U2SXk4RERFMWpvVEN5bVdoWmZQaml0V1RvVzhNb1lBejBJcy1QZzYxQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Reports Q1 2026 Result", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/earnings-watch-trisalus-life-sciences-132126206.html", "source_name": "GuruFocus.com", "published_at": "2026-05-11T13:21:26+00:00", "published_display": "11 May 2026 13:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/trisalus-tlsi-initiates-patient-enrollment-040117814.html", "source_name": "Insider Monkey", "published_at": "2026-05-10T04:01:17+00:00", "published_display": "10 May 2026 04:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxNdFRrRlJvM3J3cGJnVEJ6ZndqMnQxWkE4Wm8zTGtPTVc0OTlLN1pwNXIyclNJMFZkcG5qQTRTWThmNm9WN0hKYXBja3N3Y20zSlkxc2JaQlpYTnAyWnpvUVBvR1JWNmVxZGhSYVlYQklMd01GeFBVNGJWOFBWYUkwYmRrM2xrSktiQWpfTkZtNG1HWThNT0tqLUpYek5qcnFWMGE0QV9CaElrMUpfTEhnOC1pS2t1bkE2VVJHdEhWdEtoX2xKNE1MWk1OSlBSNTVZVU83WEpnb3E4aURwQ3ZyZUFDbndpTTZEa0lZRTJvU2VuTDhreXdCQ25iV3Y4YWxENm1xYQ?oc=5", "source_name": "StockStory", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 83, "total_relevant": 49, "sentiment_summary": {"positive": 9, "negative": 8, "neutral": 32, "score": 50, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 11.69, "count": 24}, {"event": "general", "label": "Market update", "weight": 8.25, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 4.14, "latest_week": "2026-07-10", "one_week_move": -11.7, "four_week_move": 9.8, "twelve_week_move": -11.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.638053, "market_dynamics_buy_signal": false, "relative_strength": -26.449382, "fair_value_gap": -27.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.2729, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-11.7% over one week, +9.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "www.marketscreener.com", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "GuruFocus.com", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 24}, {"label": "Market update", "count": 15}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-11.7% over one week, +9.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to sales forward of TriSalus Life Sciences, Inc. \u2013 NASDAQ:TLSI"}], "updated_at": "2026-07-16T11:42:24.297439+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}